Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain ...
Generics and biosimilars saved $445 billion in 2023, but challenges like high out-of-pocket costs, drug shortages, and ineffective policies limit their impact. AAM's report highlights the need for policy changes to ensure patient access and market sustainability.
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living ...
Johnson & Johnson submitted a Biologics License Application to the FDA for nipocalimab, seeking approval for treating generalized myasthenia gravis (gMG). The Phase 3 Vivacity-MG3 study showed superior outcomes for antibody-positive participants receiving nipocalimab plus standard of care compared to placebo plus SOC. Nipocalimab is the first FcRn blocker to demonstrate sustained disease control over six months, with consistent safety and tolerability.
Diversity, Equity & Inclusion in Clinical Trials
Clinical trials historically underrepresented women, especially women of color, in cardiovascular research. Dr. Roxana Mehran discusses the Librexia program. For more info on cardiovascular and stroke trials, visit ResearchIncludesMe.com.
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for ...
CHMP recommends daratumumab SC for newly diagnosed multiple myeloma patients eligible for ASCT, supported by PERSEUS study showing 60% reduction in disease progression or death risk with quadruplet therapy.
Regulatory actions for Sept. 23, 2024
Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Amplia, Apellis, Biocon, Biotech, Ipsen, Janssen, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Samsung Bioepis, Sanofi.
United States Urinary Tract Cancer Treatment Market By Type 2024-2031
The United States Urinary Tract Cancer Treatment Market is projected to reach USD xx.x billion by 2031, driven by advancements in medical technology, increasing prevalence of urinary tract cancers, and growing awareness about early detection and treatment options. Bladder and kidney cancers dominate the market, with treatment options including surgery, chemotherapy, radiation therapy, and immunotherapy. Future growth is expected with advancements in precision medicine, targeted therapies, and immunotherapies.
Waterloo man found guilty for fentanyl distribution, money laundering
Javoni Marcelius Butler, 43, convicted of fentanyl distribution and money laundering, faces 5-100 years in prison.
Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible
Janssen-Cilag International NV announces CHMP recommendation for DARZALEX subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem-cell transplant. Supported by Phase 3 PERSEUS study data, this aims to establish a new standard of care, enhancing progression-free survival.
Personalized Precision Medicine Market Share | 2031 Forecast
The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.
US FDA approves J&J's Rybrevant plus standard of care as first and only targeted regimen
FDA approves Rybrevant (amivantamab-vmjw) plus chemotherapy for EGFR-mutated NSCLC, showing improved progression-free survival and response rates in MARIPOSA-2 study.
© Copyright 2024. All Rights Reserved by MedPath